The latest resistance data from the European Gonococcal Antimicrobial Surveillance Programme suggest stable levels of drug resistance to cefixime, and no significant
increase in resistance to another key drug (
ceftriaxone).
Resistance to azithromycin, however, appears to be
increasing and the effectiveness of this recommended dual treatment might be under threat if resistance to third - generation cephalosporins (cefixime and
ceftriaxone) also starts to
increase again.